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Abstract
Urine is a metabolite-rich biofluid that reflects the body’s effort to
maintain chemical and osmotic homeostasis. Clinical diagnosis routinely
relies on urine samples because the collection process is easy and
noninvasive. Despite these advantages, urine is an under-investigated
source of biomarkers for multiple sclerosis (MS). Nuclear magnetic
resonance spectroscopy (NMR) has become a common approach for
analyzing urinary metabolites for disease diagnosis and biomarker
discovery. For illustration of the potential of urinary metabolites for
diagnosing and treating MS patients, and for differentiating between
MS and other illnesses, 38 urine samples were collected from healthy
controls, MS patients, and neuromyelitis optica-spectrum disorder (NMO-SD) patients and analyzed with NMR, multivariate
statistics, one-way ANOVA, and univariate statistics. Urine from MS patients exhibited a statistically distinct metabolic signature
from healthy and NMO-SD controls. A total of 27 metabolites were differentially altered in the urine from MS and NMO-SD patients
and were associated with synthesis and degradation of ketone bodies, amino acids, propionate and pyruvate metabolism, tricarboxylic
acid cycle, and glycolysis. Metabolites altered in urine from MS patients were shown to be related to known pathogenic processes
relevant to MS, including alterations in energy and fatty acid metabolism, mitochondrial activity, and the gut microbiota.
Keywords: urine biomarkers, multiple sclerosis, neuromyelitis optica-spectrum disorder, NMR, metabolomics, multivariate statistics

medication or treatment.6 Metabolites are the end products of
enzymatic reactions or protein activity that are readily modulated by genetic alterations, environmental stress, toxins, or
drugs.7 Thus, all phenotypic alteration caused by a disease or
a medical treatment is expected to exhibit a unique metabolic
profile or fingerprint.8 The ability to accurately and efficiently
detect these metabolic alterations presents a potential avenue
for personalized medicine and disease diagnosis through the
identification of metabolite biomarkers.9 Unlike a single gene
or protein routinely used as a medical biomarker, a metabolomics biomarker is commonly comprised of a dozen or more metabolites and provides a highly unique signature that may increase the likelihood of a correct diagnosis.10
The analysis of urine to obtain a metabolic profile has a
number of well-known advantages that includes ready availability; a rapid, easy, inexpensive, and noninvasive sample collection procedure; the ability to collect multiple, large samples over a range of time-points; and well-established protocols
for storing, handling, and examining urine samples.11 The

Introduction
Multiple sclerosis (MS) is a chronic disease of the central
nervous system (CNS) with both neurodegenerative and inflammatory demyelinating components.1 The disease has a heterogeneous clinical presentation and is characterized by clinical
symptoms that involve different parts of the CNS. Especially in
the early stages, MS shares features with other demyelinating
diseases like neuromyelitis optica-spectrum disorders (NMOSD).2 Despite recently updated classification criteria,3,4 differentiation between the two diseases can be difficult but nevertheless vital, because misclassification can lead to increased
disease activity due to incorrect treatment.5 Thus, the identification of metabolite biomarkers for MS may help improve MS
diagnostic protocols and help better understand the pathogenesis of the disease.
Metabolite biomarkers are small chemical entities (<1500
Da) found in biofluids where their presence or concentration has a correlation with either the prognosis, existence,
or progression of a disease or the therapeutic response to a
1

2
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investigation of urine metabolites using nuclear magnetic resonance spectroscopy (NMR) is experiencing a rapid growth of
interest, where NMR metabolomics is routinely being used for
drug and biomarker discovery.12 NMR is an attractive technique because it requires minimal sample preparations and is
able to simultaneously detect and quantify a variety of compounds from a complex mixture without separation. NMR is
commonly combined with multivariate statistics to efficiently
identify and statistically validate the metabolomics profile.13
To date, investigations into MS metabolite biomarkers has
primarily focused on the analysis of cerebrospinal fluid (CSF)
and serum samples from MS patients.14,15 Little attention has
been given to the analysis of urine16 despite the fact that metabolites excreted into urine are readily accessible and are easily detected compared to CSF or blood samples.16 We previously
reported an NMR metabolomics analysis of urinary markers of
MS using the animal model experimental autoimmune encephalomyelitis (EAE).17 The results of our prior EAE animal study
demonstrated the potential of using urine as a source of metabolite biomarkers for MS. Herein, we report an NMR metabolomics analysis of human urine samples collected from healthy
controls, MS patients, and NMO-SD patients. Our results demonstrate a statistically significant difference in the urinary metabolites observed between MS patients and healthy controls
and between MS and NMO-SD patients.
Methods and Materials
Patient Information and Clinical Manifestation
To ensure as much homogeneity as possible within the
groups, we selected definite aquaporin-4 (AQP4)-seropositive
NMO-SD patients with high antibody titers in the serum directed against the water channel AQP4, and ensured that all
were diagnosed according to the criteria proposed by Wingerchuk 2006.4 Seven of the patients had definite seropositive
NMO, whereas 2 had seropositive NMO-SD in the form of optic
neuritis (ON) and longitudinally extensive transverse myelitis
(LETM) (Table 1 and Table S1). The mean age was 39.3 with a
female predominance as expected,18 and all received immunosuppressive therapy in the form of azathioprine.
Similarly, all MS patients were diagnosed with relapsingremitting MS (RR-MS) according to the McDonald’s 2010 criteria19 and accordingly received immunomodulatory therapy.
Among this group, 5 patients received first-line therapy (glatiramer acetate and interferon-β), 1 patient received second-line
therapy (natalizumab), and 2 patients received no treatment
(Table 1 and Table S1). The mean age was 44.6 years with a
female predominance. On average, the age at disease onset
is 34 years; however, none of these patients were newly diagnosed. All healthy subjects were healthy volunteers with no
known neurological or autoimmune diseases. Neither MS nor
NMO/NMO-SD patients had experienced a relapse within 30
days of the sample collection. The study was conducted in accordance with both the Hungarian and Danish National Ethics Committee (38.93.316-12464/KK4/2010, 42341-2/2013/EKU,
S-20120066).
Urine Collection
Using the NMO-SD and MS database of the University of
Pecs in Hungary, we collected urine samples from 9 patients
with NMOSD seropositive for antibodies against AQP4, 8 patients with RRMS, and 7 healthy subjects. Treatment, age, and
gender of the study populations are shown in Table 1 and Table
S1. Urine samples were collected as spot urine in the morning
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Table 1. Demographic Data of Hungarian Cohort*

Disease Subtype
NMO-SD
ON
LETM
RR-MS
Sex
female
male
mean age (range)
Treatment
azathioprine
natalizumab
interferon β-1b
glatiramer acetate
none of the above

HS
n=7

AQP4-NMO/NMO-SD
n=9

MS
n=8

0
0
0
0

7
1
1
0

0
0
0
8

4
3

6
3

6
2

26.7 (25−30)

39.3 (22−55)

44.6 (31−70)

0
0
0
0
7

9
0
0
0
0

0
1
3
2
2

* HS, healthy subjects; AQP4, aquaporin 4; NMO, neuromyelitis optica;
NMO-SD, neuromyelitis optica-spectrum disorder; MS, multiple sclerosis; ON, optic neuritis; LETM, longitudinally extensive transverse myelitis; RR-MS, relapsing-remitting multiple sclerosis

before breakfast and administration of drug treatment and processed within 2 h of collection. The time intervals between replicate urine sample collections were variable. All patients were
on chronic treatment as indicated in Table 1 and Table S1. Azathioprine and glatiramer acetate were administered daily, interferon β-1b every other day, and natalizumab was administered once a month. In cases of interferon β-1b treatment, urine
was collected the day after administration. Urine was collected
the day before the monthly natalizumab infusion in the single
patient treated with natalizumab. Samples were centrifuged
at 20,000g for 20 min at room temperature (RT) to pellet cell
debris, and the supernatants were stored at −80 °C until use.
Except for one MS patient, two analytical replicate urine samples were obtained from each MS patient and each healthy
subject. Conversely, only one urine sample was collected from
each NMO-SD patient.
NMR Sample Preparation
The urine samples were thawed and then centrifuged at
13000 rpm for 5 min at RT to remove any precipitate. Then,
100 μL of each urine sample was transferred into a new Eppendorf tube and mixed with 500 μL of 50 mM phosphate buffer
in 99.8% D2O (Isotec, St. Louis, MO) at pH 7.2 (uncorrected);
50 μM of 3- (trimethylsilyl) propionic acid-2,2,3,3-d4 (TMSP-d4)
was added to each sample as a chemical shift reference. The
urine samples were then transferred to a 5 mm NMR tube for
NMR data acquisition.
NMR Data, Collection, and Processing and Multivariate Statistical Analysis
The one-dimensional (1D) 1H NMR experiments were collected and processed as described previously.17 The NMR data
processing and multivariate statistical analysis were accomplished using our MVAPACK software suite (http://bionmr.
unl. edu/mvapack.php).20 The 1D 1H NMR spectra were aligned
with the icoshift algorithm when the full-resolution spectra
were modeled using orthogonal projections to latent structurediscriminant analysis (OPLS-DA). Alternatively, the 1D
1H NMR spectra were binned using an intelligent adaptive binning algorithm when S-plots and a shared and unique structure
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Figure 1. (a) OPLS-DA scores resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected from MS patients
(cyan) and healthy controls (red). A statistically significant degree of separation is observed between the two experimental classes. The leaven-out cross-validation metrics are R2Y = 0.77 and Q2 = 0.39, and the CV-ANOVA and a response permutation test p-values are 7.8 × 10−4 and
8.0 × 10−3, respectively. Ellipses enclose the 95% confidence intervals estimated by the sample means and covariances of each class. (b) Response permutation testing results for OPLS-DA scores after 1000 random permutations of the group membership information (Y). The model
significance is inferred from the degree of vertical separation between the null distribution (leftmost) and the true R2Y and Q2 values (rightmost). The apparent discretization along the correlation axis is a result of using binary class labels in Y.

Figure 2. (a) Back-scaled OPLS-DA loadings plot resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected from MS patients and healthy controls. (b) S-plot from the OPLS-DA model generated from binned 1D 1H NMR spectra from the MS
and healthy controls data sets (Figure S1). The x- and y-axis of the S-plot measures the covariance and correlation, respectively. The green
and red triangles identify metabolites with a relative increase or decrease in concentration in urine samples from MS patients compared
to healthy controls, respectively. The blue triangles correspond to unknown metabolites. The black triangles correspond to all other bins or
metabolites. The metabolites are labeled as follows: 1, 2-hydroxyisovalerate; 2, isovalerate; 3, 3-hydroxyisobutyrate; 4, propylene glycol; 5,
3-hydroxybutyrate; 6, methylmalonate; 7, 3-hydroxyisovalerate; 8, lactate; 9, alanine; 10, acetate; 11, N-acetylglutamine; 12, acetone; 13,
acetoacetate; 14, oxaloacetate; 15, succinate; 16, citrate; 17, creatine; 18, creatinine; 19, malonate; 20, choline-containing compounds; 21, trimethylamine N-oxide; 22, glycine; 23, phenylalanine; 24, phenylacetylglycine; 25, hippurate; and 26, xanthine.

(SUSplot) plot were generated from the OPLS-DA model. The
data were normalized with a probabilistic quotient normalization function and Pareto scaled prior to multivariate statistical
analysis. Fractions of explained variation (R2 X and R2 Y) were
computed during OPLS-DA model training. OPLS-DA models
were internally cross-validated using 7-fold Monte Carlo crossvalidation to compute Q2 values, which were compared to a distribution of null model Q2 values in 1000 rounds of response
permutation testing. Model results were further validated using CV-ANOVA significance testing.
Metabolite Identification
An SUS plot was generated from the OPLS-DA models using MVAPACK to compare the MS and NMO-SD group against
healthy controls. The plot visualizes the correlation between
predictive components of each model and was used to identify
metabolite changes unique to either the MS or the NMO-SD
group. The chemical shift information from the loadings and
SUS plots were assigned to metabolites using Chenomx NMR
suite 7.0 (Chenomx Inc., Edmonton, Alberta, Canada) and the

Human Urine Metabolome database (http://www. urinemetabolome.ca/). A 1H chemical shift error of 0.08 ppm was used
to match the experimental chemical shifts with database values. Metabolite pathway analysis was accomplished using the
Metabolomics Pathway Analysis (MetPA) Web server (http://
metpa.metabolomics.ca/MetPA).
One-Way ANOVA and Univariate Statistical Analysis
One-way ANOVA and univariate calculations were conducted using the R statistical package version 3.2.0.21 Oneway ANOVA was used to determine the statistical significance
of individual metabolite differences between healthy, MS, and
NMO-SD patients. Metabolites with a p-value ≤ 0.05 were then
subjected to Tukey’s multiple comparison of means test to identify the set of metabolites that are statistically different between the paired groups.22 A Student’s t test was also applied to
determine the statistical significance of metabolite differences
between the two groups. The p-values from the Student’s t test
were further adjusted using the Benjamini−Hochberg multiple
hypothesis method.23

4
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Figure 3. (a) OPLS-DA scores resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected from NMO-SD
patients (cyan) and healthy controls (red). A statistically significant degree of separation is observed between the two experimental classes.
The leave-n-out cross-validation metrics are R2Y = 0.93 and Q2 = 0.68, and the CV-ANOVA and a response permutation test p-values are 7.3
× 10−3 and 0, respectively. Ellipses enclose the 95% confidence intervals estimated by the sample means and covariances of each class. (b) Response permutation testing results for OPLSDA scores after 1000 random permutations of the group membership information (Y). The model
significance is inferred from the degree of vertical separation between the null distribution (leftmost) and the true R2Y and Q2 values (rightmost). The apparent discretization along the correlation axis is a result of using binary class labels in Y.

Figure 4. (a) Back-scaled OPLS-DA loadings plot resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected
from NMO-SD patients and healthy controls. (b) S-plot from the OPLS-DA model generated from binned 1D 1H NMR spectra from NMO-SD
and healthy controls data sets (Figure S2). The x- and y-axis of the S-plot measures the covariance and correlation, respectively. The green
and red triangles identify metabolites with a relative increase or decrease in concentration in urine samples from NMO-SD patients compared to healthy controls. The blue triangles correspond to unknown metabolites. The black triangles correspond to all other bins or metabolites. The metabolites are labeled as follows: 6, methylmalonate; 8, lactate; 9, alanine; 10, acetate; 11, N-acetylglutamine; 12, acetone; 13,
acetoacetate; 14, oxaloacetate; 15, succinate; 16, citrate; 17, creatine; 18, creatinine; 19, malonate; 20, choline-containing compounds; 21, trimethylamine N-oxide; 22, glycine; 23, phenylalanine; 24, phenylacetylglycine; 25, hippurate; and 27, timethylamine.

Results
Urine Metabolomics Signature for MS Patients
A 1D 1H NMR spectrum was acquired for each of the 29
urine samples collected from seven healthy individuals and
eight patients previously diagnosed with MS. The 1D 1HNMR
spectra capture a “snapshot” of the state of the urinary metabolome and provides a direct means of determining if the
metabolic profiles differ between healthy and MS patients.
The NMR data set was modeled by OPLS-DA, and the resulting scores plot (Figure 1a) shows a clear separation between
the healthy controls and MS patients. Importantly, all of the
biological replicates were assigned to the correct class in the
OPLS-DA scores plot. The leave-n-out cross-validation metrics
of R2Y = 0.77 and Q2 = 0.39 indicates an acceptable level of fit
and predictive ability. A reliable model is also indicated by a
p-value of 7.8 × 10−4 from the CV-ANOVA test and a p-value
of 8.0 × 10−3 from the response permutation test (Figure 1b).
A back-scaled loadings plot was generated from the OPLSDA model to identify the spectral regions (metabolites) that primarily contribute to the observed class separation in the scores
plot (Figure 2a). Twenty-six metabolites are differentially

altered in the urine samples collected from healthy individuals and MS patients. The identified metabolites are from metabolic pathways associated with energy metabolism, fatty acid
synthesis, and gut microflora, which include amino acid derivatives and amino acid degradation products (Table S2). An Splot was then used to identify the major contributors to these
observed class differences in the OPLS-DA scores plot (Figures
S1 and 2b). The S-plot identified creatinine, hippurate, 3-hydroxybutyrate, malonate, oxaloacetate, and trimethylamine Noxide as having the highest covariance and correlation (from
the 26 metabolites) with the OPLS-DA model from the healthy
and MS data sets. A one-way ANOVA analysis was performed
for each metabolite identified from the multivariate statistical
analysis to determine if a statistically significant difference exists between the healthy and MS groups. Metabolites with a
p-value ≤ 0.05 were selected (Table S3) and further subjected
to Tukey’s multiple comparisons of means test.22 This analysis
indicated that the set of metabolites, including creatinine (pvalue = 4.2 × 10−4), 3- hydroxyisovalerae (p-value = 3.2 × 10−02),
and oxaloacetate (p-value = 5.0 × 10−02) discriminate between
healthy controls and MS patients (Figure S2). A Student’s t test
followed by the Benjamini−Hochberg multiple hypothesis test
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Figure 5. (a) SUS plot generated from the OPLS-DA models compare the MS and NMO-SD groups against healthy controls. NMR bins within
the MS specific or NMO-SD specific regions of the SUS plot are labeled with red or blue triangles, respectively. The resulting chemical shift
information from the SUS plot was assigned to metabolites using ChenomxNMRsuite 7.0. The metabolites are numbered accordingly: 1, 2-hydroxyisovalerate/isovalerate; 6, methylmalonate; 8, lactate; 9, alanine; 10, acetate; 16, citrate; 17, creatine; 21, trimethylamine N-oxide; and
25, hippurate. (b) Overview of the pathway topology analysis produced by MetPa (http://metpa.metabolomics.ca/MetPA). The highest ranked
pathways are numbered accordingly: 1, synthesis and degradation of ketone bodies; 2, propionate metabolism; 3, pyruvate metabolism; 4,
TCA cycle; 5, alanine, aspartate, and glutamate metabolism; and 6, glycolysis or gluconeogenesis.

(Figure S3) identified acetate and creatinine as statistically different between healthy controls and MS patients.23 The Benjamini−Hochberg adjusted p-value, one-way ANOVA, and multivariate analyses are fundamentally distinct techniques that
emphasize different aspects of the data and have no expectations of producing identical results. Thus, a subset of the eight
metabolites corresponding to acetate, creatinine, hippurate,
3-hydroxybutyrate, 3-hydroxyisovalerae, malonate, oxaloacetate, and trimethylamine N-oxide have the potential of differentiating between healthy controls and MS patients.
Urine Metabolomics Signature for NMO-SD Patients
Because NMO-SD is an inflammatory demyelinating disease of the CNS similar to MS, but antibodies play a major role
in the pathogenesis in contrast to the supposedly heterogeneous pathogenesis in MS, we considered NMO-SD as a valuable negative control for identifying biomarkers specific to MS.2
A 1D 1H NMR spectrum was acquired for each of the 23 urine
samples collected from seven healthy individuals and nine patients previously diagnosed with NMO-SD. The NMR data set
was modeled by OPLS-DA, and the resulting scores plot (Figure 3a) shows a clear separation between the healthy controls
and NMOSD patients. All of the biological replicates were assigned to the correct class in the OPLS-DA scores plot. The
leave-n-out cross-validation metrics of R2Y = 0.93 and Q2 = 0.68
indicates a reasonable level of fit and predictive ability. A reliable model is also indicated by a p-value of 7.3 × 10−3 from
the CV-ANOVA test and a p-value of zero from the response
permutation test (Figure 3b). A back-scaled loadings plot (Figure 4a) identified 20 metabolites differentially altered in the
urine samples collected from healthy individuals and NMOSD patients. The identified metabolites are amino acids and
amino acid derivatives, tricarboxylic acid (TCA) cycle intermediates, choline-containing compounds, and metabolites from
the gut microflora (Table S2). An S-plot was then used to identify the major contributors to this observed class differences
in the OPLS-DA scores plot (Figures S4 and 4b). The S-plot
identified acetate, creatinine, 3- hydroxybutyrate, methylmalonate, oxaloacetate, and succinate as having the highest covariance and correlation (from the 20 metabolites) with the OPLSDA model from the healthy and NMO-SD data sets. A one-way
ANOVA analysis was performed for each metabolite identified from the multivariate statistical analysis to determine if

a statistically significant difference exists between the healthy
and NMO-SD groups. Metabolites with a pvalue ≤ 0.05 were
selected (Table S3) and further subjected to Tukey’s multiple
comparisons of means test.22 This analysis indicated that the
set of metabolites, including creatinine (pvalue 4.0 × 10−07),
3-hydroxybutyrate (p-value 2.9 × 10−02), oxaloacetate (p-value
2.7 × 10−02), and methylmalonate (p-value 2.6 × 10−06) discriminates between healthy controls and NMOSD patients (Figure
S2). A Student’s t test followed by the Benjamini−Hochberg
multiple hypothesis test (Figure S3) also identified the same
set of metabolites as statistically different between healthy
controls and NMO-SD patients. Similar to our comparison between healthy controls and MS patients, we identified a subset of the six metabolites corresponding to acetate, creatinine,
3-hydroxybutyrate, methylmalonate, oxaloacetate, and succinate that have the potential of differentiating between healthy
controls and NMO-SD patients.
Metabolite Pathway Analysis
The complete list of 27 metabolites (Tables S2 and S4)
differentially altered in urine samples collected from MS and
NMO-SD patients relative to healthy controls were uploaded
to the MetPA Web server. MetPA used the Homo sapiens pathway library, the hypergeometric test for the over-representation analysis, and the out-degree centrality for the pathway
topology analysis. MetPA estimates a metabolite’s relative importance, provides a global overview of the metabolic changes,
and assists in identifying important pathways associated with
the disease phenotype. The synthesis and degradation of ketone bodies, amino acid metabolism, propionate metabolism,
pyruvate metabolism, the TCA cycle, and glycolysis were identified as high impact pathways in MS and NMO-SD patients
(Figure 5 and Table S5).
Urine NMR Metabolomics Signatures That Differentiate MS
and NMO-SD Patients
The two back-scaled loadings plots and the two S-plots
were directly compared to identify metabolites that were distinctly altered in the urine samples from either MS or NMOSD patients relative to healthy controls (Figures 2 and 4 and
Figure S5). Eight metabolites, alanine, hippurate, 2-hydroxyisovalerate, 3-hydroxybutyrate, isovalerate, malonate, oxaloacetate, and trimethylamine N-oxide were identified as being
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uniquely altered in urine samples from MS patients relative to
NMO-SD patients. Eight other metabolites, acetate, acetone,
citrate, creatine, creatinine, lactate, methylmalonate, and succinate were identified as being uniquely altered in urine samples from NMO-SD patients relative to MS patients.
For further refinement of a metabolic signature unique to
MS patients, an SUS plot (Figure 5a) was generated from the
MS vs healthy and the NMO-SD vs healthy OPLS-DA models
using binned NMR data (Figures S1 and S4). The two sets of
metabolites identified from the overlaid back-scaled loading
plots were then assigned to appropriate bins in the SUS plot.
In this manner, only metabolites that clearly fell within the
MS specific or NMO-SD specific regions of the SUS plot were
identified as statistically significant and retained. This analysis
reduced the number of urine metabolites specific to MS (2-hydroxyisovalerate, alanine, hippurate, isovalerate, trimethylamine N-oxide) or to NMO-SD (acetate, creatine, lactate, methylmalonate, and citrate) to five each.
The results of the multivariate statistical analysis was further supported by a follow-up univariate analysis.24 A one-way
ANOVA analysis was performed for each metabolite identified
from the multivariate statistical analysis to determine if a statistically significance difference exists between the healthy,
MS, and NMO-SD groups. Metabolites with a p-value ≤ 0.05
were selected (Table S3) and further subjected to Tukey’s multiple comparisons of means test.22 This analysis indicated that
the set of metabolites, including creatinine (p-value = 1.5 ×
10−02), 3-hydroxybutyrate (p-value = 8.0 × 10−3), 3-hydroxyisovalerate (p-value = 8.4 × 10−05), and methylmalonate (p-value
= 1.1 × 10−4), discriminate between MS and NMO-SD patients
(Figure S2). An identical set of metabolites was also obtained
using the Student’s t test followed by the Benjamini−Hochberg multiple hypothesis test (Figure S−3).23 It is important
to note that, in addition to being identified by the univariate
analysis, 3-hydroxybutyrate was also identified in both S-plots
but was absent in the SUS plot. 3-Hydroxybutyrate was likely
missing in the SUS plot due to a serendipitous cancellation because it was located in opposite regions in the two S-plots (Figures 2 and 4).
Discussion
A wide range of chemicals from food, medication, environmental contaminants, normal biological processes, and disease conditions are routinely excreted into the urine to maintain chemical homeostasis. Consequently, urinalysis has been
used to diagnose diseases and evaluate a patient’s well-being
for years. More recently, there has been a growing interest in
identifying urinary metabolite biomarkers to monitor the prognosis, existence, or progression of various cancers, cardiovascular diseases, and neurological diseases.25 Despite the highrate of misdiagnosis, little attention has been paid toward the
analysis of urinary metabolites for diagnosing MS.26 To address
this oversight, we previously demonstrated that urinary metabolites can differentiate between EAE mice (prototypic disease model for MS) from healthy and fingolimod (MS drug)treated EAE mice.17 We extended this initial animal study by
using NMR, multivariate statistics, one-way ANOVA, and univariate statistics to analyze changes in urine samples collected
from MS and NMO-SD patients. Although the sample size was
limited, we were still able to observe a potentially unique metabolic signature in urine samples collected from MS patients.
Importantly, the MS metabolic signature was likely to be distinct from the urinary metabolites identified for NMO-SD
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patients. Our results are also consistent with a recent study by
Moussallieh et al.15 that showed an increase in serum acetate
levels in NMO-SD patients relative to MS patients. However,
the limited sample size requires us to describe our statistical
model and the set of potential urinary metabolite biomarkers
as only a working hypothesis. A major revision may occur as
the number of patients per group increases significantly. Nevertheless, we are encouraged by the fact that we were able to
link all of the metabolites and metabolic pathways identified
from the urine of MS patients to known pathologic processes
associated with MS.
Glycolysis and the synthesis and degradation of ketone
bodies were identified as two potentially high-impact pathways from our NMR metabolomics analysis of urine samples
from MS patients. Specifically, we observed significant concentration changes in the glycolysis intermediates lactate and
acetate and the ketone bodies 3-hydroxybutyrate and acetoacetate. This observation is consistent with basic brain chemistry that is expected to be altered by MS. The brain has a
high energy need and uses 25% of the total available glucose.
Interestingly, the brain also uses ketone bodies as an alternative energy source.27 Thus, alteration in glycolysis and the
synthesis and degradation of ketone bodies is consistent with
an alteration in energy generation. Besides energy generation, ketone bodies are also associated with fatty acid metabolism. This is pertinent because prior analysis of CSF and serum samples from MS patients indicated altered energy and
fatty acid metabolism.28
The observed alterations in energy generation have led to
the speculation that MS might be associated with mitochondrial defects.29 In fact, Witte et al. demonstrated an occurrence
of severe mitochondrial defects in MS lesions.30 Because the mitochondria are the primary source of energy in axons, the observed defects would be expected to alter energy generation. In
the mitochondria, ATP is produced via the TCA cycle, the electron transport chain (respiratory chain), and oxidative phosphorylation. From our NMR metabolomics analysis, we identified the TCA cycle as another possible high-impact pathway
that was altered in the urine samples from MS patients. Intermediates of the TCA cycle, such as citrate, oxaloacetate, and
succinate were altered in the urine from MS patients. Of particular note, pyruvate and amino acid metabolism (alanine, aspartate, and glutamate) pathways, which are directly coupled
to the TCA cycle, were also identified as potential high-impact
pathways. Defects in the amino acid metabolism pathway are
known to cause a range of neurological issues.31
We also observed an increase in creatine and a decrease in
creatinine in the urine from MS patients. The creatine/ phosphocreatine/creatine kinase system is critical for maintaining
energy levels in the brain and as a high-energy phosphate shuttle from the mitochondria to the cytoplasm.32
Our NMR metabolomics analysis also identified propionate
metabolism as another likely high-impact pathway altered in
the urine of MS patients. Propionate (short-chain fatty acid) is
primarily derived from the catabolism of lipids (fatty acid metabolism) or proteins, where its accumulation is toxic and inhibits TCA cycle enzymes and cell growth.33 Propionate and
propionyl-CoA are detoxified by the mitochondria through the
methyl-malonyl-CoA pathway.34 Genetic flaws in the propionate metabolism pathway cause faulty amino acid and fatty
acid metabolism that lead to various neurological problems.34
Thus, the observed alteration in propionate metabolism appears to be consistent with a recent view that MS may also be
associated with dysfunction in lipid metabolism.35
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Gut microbiota are known to establish a symbiotic relationship that provides essential health benefits to the host.36
A similar correlation between gut microbiota and MS has been
previously observed.36 In fact, Cantarel et al. described a difference in specific operational taxonomic units of gut microbiota
in MS patients. Their finding also indicated that immunomodulatory medications cause alterations in the gut microbiota of
MS patients.37 Herein, we observed hippurate, a mammalian
microbial cometabolite that was altered in the urine of MS patients. Propionate (described above) is also a metabolite of the
gut microbiota. Thus, differences in urinary hippurate and propionate levels may be a result of a change in the gut microbiota or alterations in the relevant metabolic pathway.38 Taken
together, these findings suggest a potential role of gut microbiota in the pathogenesis and treatment of MS.
Conclusions
Although CNS and serum metabolites have been previously considered as a source of MS and NMO-SD biomarkers,
we have demonstrated that the urine metabolome shows significant promise for investigating and diagnosing MS and NMOSD. We observed a set of eight potential urinary metabolites
(acetate, creatinine, hippurate, 3-hydroxybutyrate, 3-hydroxyisovalerae, malonate, oxaloacetate, and trimethylamine N-oxide) associated with MS that may be prospective biomarkers.
Similarly, we observed a set of eight potential urinary metabolites (acetate, creatinine, 3-hydroxybutyrate, 3-hydroxyisovalerae, methylmalonate, oxaloacetate, and succinate) associated with NMO-SD. Critically, we observed a distinct set of
urinary metabolites (creatinine, 3-hydroxybutyrate, 3-hydroxyisovalerate, methylmalonate) that possibly differentiates MS
from NMO-SD patients. This is despite the fact that NMO-SD
is also an inflammatory immune-mediated disease of the CNS
that was once considered a variant of MS. The observation
that all of the metabolites and metabolic pathways identified
from the urine of MS patients are linked to known pathologic
processes associated with MS supports the potential reliability of our study, although the sample size was small. Specifically, metabolite changes are associated with alterations in
energy and fatty acid metabolism, mitochondrial activity, and
the gut microbiota. Although our results highlight the promise
of urinary biomarkers as a tool to diagnose MS and NMO-SD,
the limited sample size necessitates interpreting our results as
only a proof-of-principle that requires further validation. It is
possible that an increase in the number of patients per group
may lead to a change in the observed set of urinary metabolites that differentiates between MS patients, NMO-SD patients, and healthy controls. Nevertheless, as evident by a number of other recent MS and NMO-SD studies where practical
considerations limit sample size,39−43 a conservative interpretation does not negate the inherent scientific value of our observations. Instead, given the ease and ready access of urine
samples from MS and NMO-SD patients, our results establish
the urine metabolome as a potentially valuable resource for investigating the pathology of MS and NMO-SD for obtaining a
rapid and reliable diagnosis and for monitoring a patient’s response to treatment.
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